PROVIDERS

Minimal residual disease (MRD) screening with RaDaR® is available for breast, colorectal, lung, and head & neck cancers

Lung cancer

MRD tests like RaDaR have shown utility across the cancer care continuum for patients with lung cancer. 

RaDaR applicability in lung cancer

  • Risk stratification: How likely is it for your patient’s tumor to recur? Positive ctDNA result can mean your patient is at high risk of recurrence
  • Surveillance: Regular monitoring with ctDNA may give you an indication of tumor recurrence before standard of care (SOC) imaging results

ctDNA from lung cancers, particularly when in early stage, are found at very low levels in the blood, making a highly sensitive test like RaDaR an ideal choice for MRD testing in lung cancer.
 

Clinical support for ctDNA surveillance in lung cancer

RISK ASSESSMENT AND SURVEILLANCE IN STAGE I-III LUNG CANCER

In operable stages I-III non-small cell lung cancer (NSCLC), there is a significant risk of relapse after a surgery with curative intent.

The LUCID study utilized the RaDaR MRD test over the course of patient treatment.1 The study found that patients with ctDNA detected at the postsurgical, or “landmark”, timepoint had a 14.8-fold higher risk of recurrence of their primary tumor compared to patients who were found to be ctDNA-negative.

The same study was also used to monitor patients' disease, looking for early signs of disease recurrence. RaDaR detected recurrent disease a median of nearly 7 months ahead of imaging.

Graph showing recurrence-free survival rates of ctDNA not detected vs. ctDNA detected over time (days since end of treatment), as measured by RaDaR. The hazard ratio for ctDNA not detected vs. ctDNA detected was 18.8 (95% CI: 5.82-37.48), p value 1.4e-8.

ctDNA detection at the landmark timepoint is prognostic and identifies recurrence risk.

Reference: 1. Gale D, et al. Ann Oncol. 2022;33(5):500-510.

RaDaR has been carefully designed to help you detect tumor DNA in the blood with exceptional sensitivity and specificity

  • Increased accuracy with a tumor-informed, personalized panel design: RaDaR sequencing assays monitor up to 48 tumor-specific mutations, unique to each patient’s tumor, to help detect circulating tumor DNA (ctDNA)
  • Earlier detection with high sensitivity: RaDaR can detect extremely low levels of ctDNA in the blood, with a demonstrated LoD95 = 0.001% VAF. This can give additional time for important treatment management decisions
  • Fewer false positives with high specificity: RaDaR has a demonstrated analytical specificity of 100% in validation studies, giving you the confidence that comes from having more reliable results 

NeoGenomics has been supporting oncologists and pathologists in their goal to provide patients with the best care possible since 2002.

LoD95 = limit of detection, working at a confidence of 95%; VAF = variant allele fraction.

LEARN MORE

How to order a RaDaR test

CLIENT SERVICES

NeoGenomics prides itself on its unparalleled customer support team. If you have questions regarding test information, specimen requirements, turnaround times, test add-on, and test results, please feel free to reach out to a Client Services Advocate at client.services@neogenomics.com or call 866.776.5907, option 3.

ONLINE ORDERING

Online Ordering streamlines and simplifies your test-ordering process into a single time-saving, easy-to-use experience.

LOGIN TO NEOLINK®

PAPER ORDER FORMS

Complete a RaDaR test requisition form.

New to NeoGenomics? Call the NeoGenomics Client Services team at 866.776.5907 and press 3 to set up an account.

ACCESS THE RaDaR REQUISITION FORM

Investigator-Initiated Trials

NeoGenomics recognizes the important role of externally driven scientific research to expand medical knowledge and define the clinical utility of our tests in a real-world setting.

Investigator-Initiated Trials (IIT) request form

Get started with RaDaR

Contact us to order a RaDaR test.